BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers (Basel) 2021;13:2878. [PMID: 34207685 DOI: 10.3390/cancers13122878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kang MA, Rao PP, Matsui H, Mahajan SS. Delivery of mGluR5 siRNAs by Iron Oxide Nanocages by Alternating Magnetic Fields for Blocking Proliferation of Metastatic Osteosarcoma Cells. IJMS 2022;23:7944. [DOI: 10.3390/ijms23147944] [Reference Citation Analysis]
2 Chirio D, Sapino S, Chindamo G, Peira E, Vercelli C, Riganti C, Manzoli M, Gambino G, Re G, Gallarate M. Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy. Pharmaceutics 2022;14:1362. [DOI: 10.3390/pharmaceutics14071362] [Reference Citation Analysis]
3 Mizerska-Kowalska M, Sowa S, Donarska B, Płaziński W, Sławińska-Brych A, Tomasik A, Ziarkowska A, Łączkowski KZ, Zdzisińska B. New Borane-Protected Derivatives of α-Aminophosphonous Acid as Anti-Osteosarcoma Agents: ADME Analysis and Molecular Modeling, In Vitro Studies on Anti-Cancer Activities, and NEP Inhibition as a Possible Mechanism of Anti-Proliferative Activity. Int J Mol Sci 2022;23:6716. [PMID: 35743158 DOI: 10.3390/ijms23126716] [Reference Citation Analysis]
4 Gallego B, Murillo D, Rey V, Huergo C, Estupiñán Ó, Rodríguez A, Tornín J, Rodríguez R. Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models. Int J Mol Sci 2022;23:6425. [PMID: 35742867 DOI: 10.3390/ijms23126425] [Reference Citation Analysis]
5 Zeng Z, Li W, Zhang D, Zhang C, Jiang X, Guo R, Wang Z, Yang C, Yan H, Zhang Z, Wang Q, Huang R, Zhao Q, Li B, Hu X, Gao L. Development of a Chemoresistant Risk Scoring Model for Prechemotherapy Osteosarcoma Using Single-Cell Sequencing. Front Oncol 2022;12:893282. [PMID: 35664733 DOI: 10.3389/fonc.2022.893282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen T, Liu J, Zhang H, Li J, Shang G. Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma. Front Oncol 2022;12:907472. [DOI: 10.3389/fonc.2022.907472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhao J, Zhao Y, Ma X, Feng H, Jia L. Outstanding prognostic value of novel ferroptosis-related genes in chemoresistance osteosarcoma patients. Sci Rep 2022;12:5029. [PMID: 35322804 DOI: 10.1038/s41598-022-09080-5] [Reference Citation Analysis]
8 Fontana F, Anselmi M, Limonta P. Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression. Cancers (Basel) 2022;14:1614. [PMID: 35406386 DOI: 10.3390/cancers14071614] [Reference Citation Analysis]
9 Liu J, Shang G. The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets. Front Cell Dev Biol 2022;10:773038. [PMID: 35252166 DOI: 10.3389/fcell.2022.773038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Perut F, Graziani G, Roncuzzi L, Zini N, Avnet S, Baldini N. FT-IR Spectral Signature of Sensitive and Multidrug-Resistant Osteosarcoma Cell-Derived Extracellular Nanovesicles. Cells 2022;11:778. [DOI: 10.3390/cells11050778] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu D, Wang R, Wang Y, Wang Y, Wang L. Prospero homeobox 1 promotes proliferation, migration, and invasion of osteosarcoma cells and its clinical significance. Bioengineered 2022;13:2259-71. [PMID: 35030967 DOI: 10.1080/21655979.2021.2024330] [Reference Citation Analysis]
12 Huang X, Zhang W, Pu F, Zhang Z. LncRNA MEG3 promotes chemosensitivity of osteosarcoma by regulating antitumor immunity via miR-21-5p/p53 pathway and autophagy. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.11.004] [Reference Citation Analysis]
13 Bădilă AE, Rădulescu DM, Niculescu AG, Grumezescu AM, Rădulescu M, Rădulescu AR. Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review. Cancers (Basel) 2021;13:4229. [PMID: 34439383 DOI: 10.3390/cancers13164229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]